Inhibikase Therapeutics, Inc. (IKT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 10.26M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 127.81M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $10.26M | (m) | $127.81M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $5.71M | (m) | $120.80M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $8.30M | $178.80M | $39.54M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $6.70M | (m) | $39.05M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $8.80M | (m) | $9.92M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $8.55M | (m) | $19.74M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $3.73M | $56.50M | $41.05M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $4.91M | (m) | $2.33M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $3.70M | (m) | $4.85M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $4.23M | (m) | $7.40M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $3.44M | $9.17M | $4.09M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $2.74M | (m) | $1.97M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $2.73M | (m) | $19.03M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $2.66M | (m) | $21.76M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $3.70M | $7.19M | $15.86M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $3.21M | (m) | $20.75M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $4.05M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $2.71M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $1.91M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $3.59M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $4.72M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |